Trevor Allred Analyst Performance

Senior Analyst, Biotechnology at Oppenheimer

Trevor Allred is a stock analyst at Oppenheimer in the medical sector, covering 4 publicly traded companies. Over the past year, Trevor Allred has issued 6 stock ratings, including and buy recommendations. While full access to Trevor Allred's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Trevor Allred's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 6 Last 0 Years
Buy Recommendations: 100.00% 6 Buy Ratings
Companies Covered: 4 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	100.0%	6 ratings
Hold	0.0%	0 ratings
Sell	0.0%	0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	75.0% of companies on NASDAQ	3 companies
NYSE	25.0% of companies on NYSE	1 company

Trevor Allred, an analyst at Oppenheimer, currently covers 4 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 4 companies	100.0%

Trevor Allred of Oppenheimer specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 2 companies	50.0%
LARGE CAP PHARMA 1 company	25.0%
PHARMACEUTICAL PREPARATIONS 1 company	25.0%

About Trevor Allred

Trevor Allred is a Senior Analyst covering Biotechnology. Trevor has been with Oppenheimer since 2019. Prior to joining Oppenheimer, Trevor spent over five years working as a Clinical Laboratory Scientist before pursuing his MBA. Trevor holds a Bachelor of Science degree in Medicinal Chemistry and Molecular Pharmacology from Purdue University, and a Master in Business Administration from Indiana University’s Kelley School of Business.

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
PVLA Palvella Therapeutics	9/9/2025	Initiated Coverage	$55.02	$85.00	Outperform
LGND Ligand Pharmaceuticals	9/3/2025	Boost Price Target	$165.95	$190.00	Outperform
INVA Innoviva	8/11/2025	Initiated Coverage	$18.34	$45.00	Outperform
LGND Ligand Pharmaceuticals	7/30/2025	Boost Price Target	$134.13	$162.00	Outperform
MBX MBX Biosciences	7/16/2025	Initiated Coverage	$13.40	$38.00	Outperform
LGND Ligand Pharmaceuticals	5/9/2025	Boost Price Target	$106.35	$145.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.